Outcome of Initial Progression During Nivolumab Treatment for Hepatocellular Carcinoma: Should We Use iRECIST?

Frontiers in Medicine

Young Hwan Koh¹  Kyung-Hun Lee²  Sangyoun Hwang³  Ju Yeon Kim⁴  Yoon Jun Kim⁴  Jung-Hwan Yoon⁴  Jeong-Hoon Lee⁴  Dong Ho Lee⁶  Joong-Won Park⁷ 

[1] Medical Sciences, Busan, South Korea;Center for Liver and Pancreato-Biliary Cancer, National Cancer Center, Goyang, South Korea;;Department of Internal Medicine, Dongnam Institute of Radiological &Department of Internal Medicine, Seoul National University College of Medicine, Seoul, South Korea;Department of Radiology, Seoul National University Hospital, Seoul, South Korea;Institute of Radiation Medicine, Seoul National University Hospital, Seoul, South Korea;Liver Research Institute, Seoul National University College of Medicine, Seoul, South Korea;

关键词: liver cancer;    iRECIST;    pseudoprogression;    progression;    nivolumab;   

DOI  :  10.3389/fmed.2021.771887

来源: DOAJ

【 摘 要 】

Immune response evaluation criteria in solid tumors (iRECIST) is recommended during immune checkpoint inhibitors (ICIs) treatment, due to the possibility of pseudoprogression. We evaluated the frequency of pseudoprogression in hepatocellular carcinoma (HCC) patients. This retrospective multicenter study involved 158 consecutive patients who underwent nivolumab treatment for HCC in Korea. At the initial evaluation, 94 patients presented with immune unconfirmed progressive disease, and 22 continued nivolumab. At the second evaluation, 21 of the 22 patients (95.5%) had confirmed progression and no pseudoprogression was observed. Considering low possibility of pseudoprogression, iRECIST may not be required for HCC.

【 授权许可】

Unknown